淋巴结转移是阴茎癌（PeCa）、恶性黑色素瘤等患者生存预后的相关预测因素。哨兵淋巴结（SN）程序包括有针对性地切除第一个肿瘤引流的哨兵淋巴结。多年来，杂交示踪剂吲哚青绿（ICG）-99mTc纳米胶体被用于将光学和核探测相结合。最近，纳米胶体前体资源停止生产，被另一种化学相似但不同的胶体纳米扫描取代了。我们的目的是从核医学和外科角度研究ICG-99mTc纳米扫描与ICG-99mTc纳米胶体的性能。纳入24名接受SN程序的阴茎癌或头颈部黑素瘤患者。最初的11名患者接受ICG-99mTc纳米胶体，直到停产；第二组13名接受ICG-99mTc纳米扫描。淋巴显像和单光子发射（SPECT）评估示踪剂摄取情况。术中，使用伽马示踪和荧光成像识别哨兵淋巴结。进行离体（台上）测量以量化荧光发射。进行化学分析以比较两种胶体前体上的ICG组装。哨兵淋巴结的平均示踪剂摄取量在ICG-99mTc纳米胶体组（2.2±4.3％ID）和ICG-99mTc纳米扫描组（1.8±2.6％ID；p = 0.68）中相似。在接受ICG-99mTc纳米扫描的阴茎癌患者中，淋巴显像检测到3个哨兵淋巴结（四分位距（IQR）为3-4），而接受ICG-99mTc纳米胶体的患者为2个哨兵淋巴结（IQR为2-3）（p = 0.045），头颈部黑素瘤患者没有观察到差异。切除哨兵淋巴结后的离体测量显示ICG-99mTc纳米扫描组（24×109任意单位（A.U。）IQR为1.6×109-14×109）的总荧光强度较低，在ICG-99mTc纳米胶体组中为4.6×109A.U。特征相关性分析结果表明纳米扫描配方观察到更大程度的“堆叠”ICG（IQR为2.4×109-42×109，p = 0.0054）。未报告示踪剂相关的不良事件。根据这次回顾性分析，我们可以得出结论：ICG-99mTc纳米扫描与ICG-99mTc纳米胶体具有相似的哨兵淋巴结识别能力，并且可以安全地用于哨兵淋巴结程序。 ©2023.作者。

Lymph node (LN) metastasis is a relevant predictor for survival in patients with a.o. penile cancer (PeCa), malignant melanoma. The sentinel node (SN) procedure comprises targeted resection of the first tumour-draining SNs. Here, the hybrid tracer indocyanine green (ICG)-99mTc-nanocolloid has been used for several years to combine optical and nuclear detection. Recently, the resource of the nanocolloid precursor stopped production and the precursor was replaced by a different but chemically comparable colloid, nanoscan. Our aim was to study the performance of ICG-99mTc-nanoscan compared to ICG-99mTc-nanocolloid from a nuclear and surgical perspective.Twenty-four patients with either PeCa or head-and-neck (H&N) melanoma and scheduled for a SN procedure were included. The initial group (n = 11) received ICG-99mTc-nanocolloid until no longer available; the second group (n = 13) received ICG-99mTc-nanoscan. Tracer uptake was assessed on lymphoscintigraphy and single-photon emission (SPECT). Intraoperatively, SNs were identified using gamma tracing and fluorescence imaging. Ex vivo (back-table) measurements were conducted to quantify the fluorescence emissions. Chemical analysis was performed to compare the ICG assembly on both precursors.The mean tracer uptake in the SNs was similar for ICG-99mTc-nanocolloid (2.2 ± 4.3%ID) and ICG-99mTc-nanoscan (1.8 ± 2.6%ID; p = 0.68). 3 SNs (interquartile range (IQR) 3-4) were detected on lymphoscintigraphy in PeCa patients receiving ICG-99mTc-nanoscan compared to 2 SNs (IQR 2-3) in PeCa patients receiving ICG-99mTc-nanocolloid (p = 0.045), no differences were observed in H&N patients. Back-table measurements of resected SNs revealed a lower total fluorescence intensity in the ICG-99mTc-nanoscan group (24*109 arbitrary units (A.U) IQR 1.6*109-14*109 in the ICG-99mTc-nanocolloid group versus 4.6*109 A.U. IQR 2.4*109-42*109 in the ICG-99mTc-nanoscan group, p = 0.0054). This was consistent with a larger degree of "stacked" ICG observed in the nanoscan formulation. No tracer-related adverse events were reported.Based on this retrospective analysis, we can conclude that ICG-99mTc-nanoscan has similar capacity for SN identification as ICG-99mTc-nanocolloid and can safely be implemented in SN procedures.© 2023. The Author(s).